This week in Drug Discovery (14-18 September 2026)
News round-up for 14-18 September 2026 by Megan Thomas, Content Team at DDW.
This week’s news roundup covers the upcoming Drug Discovery Innovators & Investors Digital Forum and the Drug Discovery Innovators & Investors Conference in London, changes to US scientific research grant screening, the UK’s role in global drug development, and clinical advances in lung cancer and liver disease therapies.
The top stories:
Less than two weeks until Drug Discovery Innovators & Investors Digital Forum
Experts from across the drug discovery ecosystem will explore the technologies, strategies, therapies and investment trends shaping early-stage drug discovery at the Drug Discovery Innovators & Investors (DDII) Digital Forum on 30 September.
Researchers challenge NIH screening of scientific research grants
US researchers have filed a class action lawsuit challenging the National Institutes of Health’s (NIH) policy of blocking grants to censor views it disagrees with, on everything from DEI to gender identity to climate change.
Chris Molloy, Chief Executive Officer of the UK BioIndustry Association (BIA), will explore the UK’s role in the changing global drug R&D landscape in his keynote address at the Drug Discovery Innovators & Investors (DDII) UK Conference on 4 November 2026 at etc.venues Monument, London, UK.
Amivantamab shown to extend survival in advanced NSCLC
Johnson & Johnson has announced final overall survival (OS) results from the Phase III PAPILLON study of first-line intravenous (IV) Rybrevant (amivantamab).
Macrophage therapy trial in liver disease completes enrolment
The final patient has been treated in EMERALD, Resolution Therapeutics’ Phase I/II clinical trial evaluating its engineered Regenerative Macrophage Therapy (RMT), RTX001, in patients with end-stage liver disease (ESLD) and a history of decompensated liver cirrhosis.
